Drug Type Synthetic peptide vaccine, Therapeutic vaccine |
Synonyms LabVax, LabVax 3(22)-23, Labvax 3(22)-23 + [1] |
Target |
Mechanism Labyrinthin inhibitors(Labyrinthin inhibitors), Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenocarcinoma | Phase 2 | US | 02 Nov 2023 | |
Adenocarcinoma, metastatic | Phase 2 | US | 13 Oct 2021 | |
Advanced Lung Adenocarcinoma | Phase 2 | US | 13 Oct 2021 | |
Advanced Malignant Solid Neoplasm | Phase 2 | US | 13 Oct 2021 | |
Metastatic Solid Tumor | Phase 2 | US | 13 Oct 2021 | |
Recurrent Gastroesophageal Junction Adenocarcinoma | Phase 2 | US | 13 Oct 2021 | |
Relapsed Solid Neoplasm | Phase 2 | US | 13 Oct 2021 |
Phase 1/2 | Adenocarcinoma Labyrinthin (LAB) | 12 | maawthktds(ctxafntrnd) = svlwnezhfj imjqmpdxvv (gdsvqblkyl ) | Positive | 02 Nov 2023 | ||
maawthktds(ctxafntrnd) = nbzapkmdds imjqmpdxvv (gdsvqblkyl ) | |||||||
Phase 1 | Adenocarcinoma Adjuvant | 10 | kuquwygzyf(iapewvtzsu) = rivjbrfvlv jlsqzdotug (rftgeinlcn ) View more | Positive | 26 May 2023 |